Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking

被引:42
作者
Luque-Ramirez, Manuel [1 ,2 ]
Mendieta-Azcona, Covandonga [3 ]
del Rey Sanchez, Jose M. [4 ]
Maties, Milagro [4 ]
Escobar-Morreale, Hector F. [1 ,2 ]
机构
[1] Hosp Univ Ramon y Cajal, Dept Endocrinol, E-28034 Madrid, Spain
[2] Univ Alcala de Henares, E-28034 Madrid, Spain
[3] Hosp Univ La Paz, Dept Vasc Surg, E-28046 Madrid, Spain
[4] Hosp Univ Ramon y Cajal, Dept Clin Biochem, E-28034 Madrid, Spain
关键词
PLUS CYPROTERONE-ACETATE; NORMAL-WEIGHT WOMEN; INSULIN-RESISTANCE; ETHINYL-ESTRADIOL; CIGARETTE-SMOKING; YOUNG-WOMEN; VENOUS THROMBOEMBOLISM; HOMOCYSTEINE LEVELS; ANDROGEN EXCESS; RISK-FACTOR;
D O I
10.1530/EJE-08-0725
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To study the blood clotting tests and endothelial function of polycystic ovary syndrome (PCOS) patients and non-hyperandrogenic women, and their changes during PCOS treatment, as a function of the presence of obesity and smoking. Design: Case-control study followed by a randomized clinical trial. Methods: Blood clotting and endothelial function were analyzed in 40 PCOS patients and 20 non-hyperandrogenic women. Thirty-four PCOS women were randomized to an oral contraceptive containing 35 mu g ethinyl-estradiol plus 2 mg cyproterone acetate (Diane(35)Diario) or metformin (850 mg twice daily), monitoring the changes on these parameters during 24 weeks of treatment. The influence of obesity and smoking was also analyzed. Results: Blood clotting and endothelial function tests were similar among PCOS patients and controls with the exception of a higher platelet count in the former. Obesity increased circulating fibrinogen levels. prothrombin activity and platelet counts. and reduced prothrombin and activated partial thromboplastin times. Smoking increased fibrinogen levels, platelet counts, and prothrombin activity. and reduced prothrombin time, in relation to the larger waist circumference of smokers. Irrespective of the treatment received, PCOS patients showed a decrease in prothrombin time and all increase ill prothrombin activity, with a parallel increase in homocysteine levels in metformin users. The activated partial thromboplastin time decreased markedly in the patients treated with Diane(35)Diario. Finally, flow-mediated dilation improved in non-smokers irrespective of the drug received, but worsened in smokers. Conclusions: Oral contraceptives and metformin may exert deleterious effects on blood clotting tests of PCOS women. yet the effects of metformin appear to be milder. Because smoking potentiates some of these effects and deteriorates endothelial function, smoking cessation should be promoted in PCOS patients.
引用
收藏
页码:469 / 480
页数:12
相关论文
共 58 条
[21]   Abdominal adiposity and the polycystic ovary syndrome [J].
Escobar-Morreale, Hector F. ;
Millan, Jose L. San .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2007, 18 (07) :266-272
[22]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J].
Fauser, BCJM ;
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
HUMAN REPRODUCTION, 2004, 19 (01) :41-47
[23]   Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy [J].
Franks, Stephen ;
Layton, Alison ;
Glasier, Anna .
HUMAN REPRODUCTION, 2008, 23 (02) :231-232
[24]   HOMOCYSTEINE, A RISK FACTOR FOR PREMATURE VASCULAR-DISEASE AND THROMBOSIS, INDUCES TISSUE FACTOR ACTIVITY IN ENDOTHELIAL-CELLS [J].
FRYER, RH ;
WILSON, BD ;
GUBLER, DB ;
FITZGERALD, LA ;
RODGERS, GM .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (09) :1327-1333
[25]   Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome [J].
Jensterle, Mojca ;
Sebestjen, Miran ;
Janez, Andrej ;
Prezelj, Janez ;
Kocjan, Tomaz ;
Keber, Irena ;
Pfeifer, Marija .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 159 (04) :399-406
[26]   RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS [J].
JICK, H ;
JICK, SS ;
GUREWICH, V ;
MYERS, MW ;
VASILAKIS, C .
LANCET, 1995, 346 (8990) :1589-1593
[27]   Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance [J].
Ketel, Iris J. G. ;
Stehouwer, Coen D. A. ;
Serne, Erik H. ;
Korsen, Ted J. M. ;
Hompes, Peter G. A. ;
Smulders, Yvo M. ;
de Jongh, Renate T. ;
Homburg, Roy ;
Lambalk, Cornelis B. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (09) :3365-3372
[28]   Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study [J].
Kilicdag, EB ;
Bagis, T ;
Zeyneloglu, HB ;
Tarim, E ;
Aslan, E ;
Haydardedeoglu, B ;
Erkanli, S .
HUMAN REPRODUCTION, 2005, 20 (04) :894-899
[29]   Polycystic ovary syndrome and cardiovascular disease: A premature association? [J].
Legro, RS .
ENDOCRINE REVIEWS, 2003, 24 (03) :302-312
[30]   Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size [J].
Liang, YL ;
Teede, H ;
Kotsopoulos, D ;
Shiel, L ;
Cameron, JD ;
Dart, AM ;
McGrath, BP .
CLINICAL SCIENCE, 1998, 95 (06) :669-679